Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal up2.700 +0.010 (+0.372%)
Others

26/02/2021 09:58

Luye Pharma (02186) gets clinical trial application accepted

[ET Net News Agency, 26 February 2021] Luye Pharma Group Ltd. (02186) said the clinical
trial application in relation to Nivolumab injection (LY01015) of Shandong Boan
Biotechnology Co. Ltd. (a subsidiary of the company) has been formally accepted by the
Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in
the People's Republic of China.
LY01015 is indicated for the treatment of patients with melanoma, non-small cell lung
cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma (RCC), etc. (RC)

Back to Others

Remark: Real time quote last updated: 25/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.